Showing 2,658 results

Filters Content type: News, Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Hepatitis C treatment

Hepatitis C virus relapse uncommon after sustained virological response

Editor's pick
Medscape
17 February 2016
Hepatitis C treatment

U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease

Editor's pick
Gilead press release
17 February 2016
Hepatitis C treatment

12 Feb 2016: My day of reckoning

Editor's pick
Hep Magazine
12 February 2016
Organ transplants

Survival and outcome analysis shows that selected HIV-positive patients are good candidates for liver and kidney transplant

News
11 February 2016
Prisoners

New Report and Monitoring Tool: HIV, HCV, TB and Harm Reduction in Prisons

Editor's pick
Harm Reduction International
10 February 2016
Access to healthcare

Are States Obligated To Provide Expensive Hepatitis C Drugs?

Editor's pick
Kaiser Health News
10 February 2016
Hepatitis C treatment

New cases of hepatitis C in NYC are on the rise

Editor's pick
Politico
9 February 2016
Hepatitis C treatment

mapCrowd: an online data collection platform for hepatitis C information

Editor's pick
Treatment Action Group
9 February 2016
Organ transplants

Johns Hopkins approved to perform first HIV-positive to HIV-positive organ transplants in U.S.

Editor's pick
Johns Hopkins Medicine
9 February 2016
Hepatitis C treatment

Olysio/Sovaldi yield high SVR post-liver transplant

Editor's pick
Healio
8 February 2016
New & experimental hepatitis C treatment

Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

Editor's pick
Fair Pricing Coalition
8 February 2016
New & experimental hepatitis C treatment

U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Editor's pick
Bristol-Myers Squibb press release
8 February 2016
Hepatitis C treatment

Pennsylvania to Offer Free Hepatitis C Treatment to Low-Income People With HIV

Editor's pick
Poz magazine news
5 February 2016
Activism & civil society

Lawsuits claim insurers unfairly refuse pricey hepatitis C drugs

Editor's pick
Seattle Times
3 February 2016
Hepatitis C treatment

Lawmaker: Costly hepatitis C drug "a slap in the face to veterans"

Editor's pick
CBS News
3 February 2016
Pharmaceutical industry

Merck Throws a Wrench in Drug Pricing

Editor's pick
Bloomberg
1 February 2016
New & experimental hepatitis C treatment

New Merck combination pill Zepatier approved for hepatitis C treatment in the United States

News
1 February 2016
New & experimental hepatitis C treatment

Zepatier for hepatitis C approved in Canada

Editor's pick
CATIE
1 February 2016
Hepatitis C treatment

European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV

Editor's pick
Bristol-Myers Squibb press release
1 February 2016
Hepatitis C treatment

Merck Prices Hepatitis C Drug Lower Than Rivals in Crowded Field

Editor's pick
Bloomberg
29 January 2016
New & experimental hepatitis C treatment

Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults

Editor's pick
Merck press release
29 January 2016
Hepatitis C transmission & prevention

HCV on the Rise in Dialysis Patients, CDC Warns

Editor's pick
MedPage Today HIV/AIDS
29 January 2016
Hepatitis C treatment

California Doles Out Millions to Insurers for Hepatitis C Drugs

Editor's pick
KQED News
29 January 2016
Hepatitis C treatment

Kansas Legislators Walk Back On Lifetime Ban For Hepatitis C Drugs

Editor's pick
KCUR
24 January 2016